OneMedNet (ONMD)

Search documents
OneMedNet (ONMD) - 2022 Q3 - Quarterly Report
2022-11-18 22:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40386 Data Knights Acquisition Corp. (Exact name of registrant as specified in its charter) | Delaware | 86-2076743 | | ...
OneMedNet (ONMD) - 2022 Q2 - Quarterly Report
2022-08-15 19:10
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40386 Data Knights Acquisition Corp. (Exact name of registrant as specified in its charter) | Delaware | 86-2076743 | | --- ...
OneMedNet (ONMD) - 2022 Q1 - Quarterly Report
2022-05-16 18:48
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40386 Data Knights Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2076743 (State or o ...
OneMedNet (ONMD) - 2021 Q4 - Annual Report
2022-04-01 17:02
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40386 Data Knights Acquisition Corp. | (Exact name of registrant as specified in its charter) | Delaware | 86-2076743 ...
OneMedNet (ONMD) - 2021 Q3 - Quarterly Report
2021-11-15 22:02
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40386 Data Knights Acquisition Corp. (Exact name of registrant as specified in its charter) | Delaware | 86-2076743 | | ...
OneMedNet (ONMD) - 2021 Q2 - Quarterly Report
2021-08-16 18:25
PART I [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents Data Knights Acquisition Corp.'s unaudited condensed financial statements for the period ended June 30, 2021, reflecting its post-IPO financial position as a blank check company - Data Knights Acquisition Corp., a blank check company incorporated on February 8, 2021, focuses on effecting a business combination, with all activities to date related to its formation and IPO[17](index=17&type=chunk)[18](index=18&type=chunk) Condensed Balance Sheet as of June 30, 2021 (Unaudited) | Category | Amount (USD) | | :--- | :--- | | **Total Assets** | **$118,112,904** | | Cash | $802,110 | | Cash held in Trust Account | $117,300,794 | | **Total Liabilities** | **$10,250,850** | | Warrant liability | $6,174,038 | | Deferred underwriter fee payable | $4,025,000 | | Class A common stock subject to possible redemption | $102,862,053 | | **Total Stockholders' Equity** | **$5,000,001** | Condensed Statement of Operations (For the period from Feb 8, 2021 to June 30, 2021) | Category | Amount (USD) | | :--- | :--- | | Formation and operating costs | $(71,339) | | Interest earned on Trust Account | $794 | | Change in Fair value of warrant liability | $5,002,911 | | **Net Income** | **$4,307,307** | - The company consummated its IPO of **11.5 million units** on May 11, 2021, generating **$115 million** in gross proceeds, alongside selling **585,275 private placement units** to the Sponsor for **$5.85 million**[19](index=19&type=chunk)[20](index=20&type=chunk) - Post-IPO, **$117.3 million** was placed in a Trust Account, with IPO transaction costs totaling **$6.77 million**, including **$4.025 million** in deferred underwriting fees[21](index=21&type=chunk)[22](index=22&type=chunk) - The company must consummate a Business Combination by May 11, 2022 (extendable to November 11, 2022), or face liquidation and redemption of public shares[25](index=25&type=chunk) - The company's **12,085,275 warrants** are recognized as a fair value liability, with changes recorded in the statement of operations, as they do not qualify for equity treatment under ASC 815-40[72](index=72&type=chunk)[85](index=85&type=chunk)[86](index=86&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's analysis of the company's financial condition and results, highlighting its pre-business combination status, non-operational revenue, and liquidity for identifying a target - Formed on February 8, 2021, the blank check company's activities have focused on organization, IPO preparation, and identifying a business combination target[95](index=95&type=chunk)[99](index=99&type=chunk) Results of Operations (Feb 8, 2021 - June 30, 2021) | Category | Amount (USD) | | :--- | :--- | | Net Income | $4,307,307 | | **Components:** | | | Change in Fair Value of warrant liability | $5,002,911 | | Interest income on marketable securities | $794 | | Operating costs | $(71,340) | | Non-operating costs | $(625,058) | - As of June 30, 2021, the company held **$802,110** in cash and **$760,298** in working capital to fund its search for a business combination target[103](index=103&type=chunk) - The Sponsor may provide Working Capital Loans up to **$1.5 million** for transaction costs, convertible into units at **$10.00 per unit** upon Business Combination consummation[105](index=105&type=chunk) - A contractual obligation exists to reimburse a Sponsor affiliate up to **$10,000 per month** for administrative support until a Business Combination or liquidation[109](index=109&type=chunk) - A deferred underwriting commission of **$4.025 million** is payable from the Trust Account solely upon the completion of an initial Business Combination[110](index=110&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section indicates minimal market risk, as IPO proceeds and Trust Account funds are invested in short-term U.S. government treasury securities or money market funds - Company funds, including those in the Trust Account, are invested in short-term U.S. government treasury securities or money market funds[122](index=122&type=chunk) - Given the short-term nature of its investments, the company does not anticipate material exposure to interest rate risk[122](index=122&type=chunk) [Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) This section confirms the effectiveness of the company's disclosure controls and procedures as of June 30, 2021, with no material changes to internal control over financial reporting during the quarter - As of June 30, 2021, principal executive and financial officers concluded that disclosure controls and procedures were effective[125](index=125&type=chunk) - No material changes occurred in the company's internal control over financial reporting during the quarter ended June 30, 2021[126](index=126&type=chunk) PART II [Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no involvement in any legal proceedings - The company is not involved in any legal proceedings[129](index=129&type=chunk) [Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors) No material changes have occurred to the risk factors previously disclosed in the company's final prospectus filed on May 6, 2021 - No material changes have been made to the risk factors disclosed in the company's final prospectus dated May 6, 2021[130](index=130&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=33&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the private sale of **585,275 units** to the Sponsor for **$5.85 million** and the allocation of IPO proceeds, including **$117.3 million** to a trust account - On May 11, 2021, the company sold **585,275 Private Placement Units** to the Sponsor at **$10.00 per unit**, generating **$5.85 million** in gross proceeds through an unregistered sale[131](index=131&type=chunk) - From IPO and private placement proceeds, **$117.3 million** was deposited into a Trust Account, with **$2.3 million** paid in underwriting discounts and commissions, **$652,750** in other costs, and **$4.025 million** in deferred underwriting fees[135](index=135&type=chunk) [Defaults Upon Senior Securities](index=33&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults on its senior securities - The company has no defaults upon senior securities[136](index=136&type=chunk) [Mine Safety Disclosures](index=33&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - Not Applicable[137](index=137&type=chunk) [Other Information](index=33&type=section&id=Item%205.%20Other%20Information) The company reports no additional information for the period - No other information is reported for the period[137](index=137&type=chunk) [Exhibits](index=35&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including certifications from the Principal Executive and Financial Officers and Inline XBRL documents - The report includes required certifications from the CEO and CFO under Sections 302 and 906 of the Sarbanes-Oxley Act, alongside Inline XBRL filings[139](index=139&type=chunk)
OneMedNet (ONMD) - 2021 Q1 - Quarterly Report
2021-06-21 18:35
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40386 Data Knights Acquisition Corp. (Exact name of registrant as specified in its charter) | Delaware | 86-2076743 | | --- | --- | | (State ...